One aspect of the invention provides a method for treating or preventing the development of osteoarthritis by administering to a subject in need of such treatment a composition including a therapeutically effective amount of an anti-fibrotic agent. In various embodiments, the anti-fibrotic agent is 5-methyl-1-phenylpyridin-2-one, tranilast, gamma-glutamyl transpeptidase inhibitor, fasudil, CC-930, T-5524, rosiglitazone, tocilizumab, E5564, TAK-242, GKT136901 or bosentan.

The present invention provides positron emitter radiolabeled versions of PABA, metabolites and derivatives, with good radiochemical yield, high specific activity, high chemical and radiochemical purity and having excellent characteristics for PET imaging. The inventive composition and methods provide high quality dynamic images of the kidneys while reducing the radiation exposure. The short biological half-life of PABA, added to the short physical half-life of positron emitters such as .sup.11C will also benefit patients that require multiple renography assessments in a short period of time.

The present invention relates to photohexer compounds and a pharmaceutical composition and use thereof. Specifically, the present invention relates to 2(4)-(1-hexyloxy-ethyl)-6,7-bispropionate-1,3,5,8-tetramethyl-4(2)-vinylpor-phyrin and their analogues, which are water soluble, have stable properties, can be used as a photosensitizer, and are suitable for the diagnosis and treatment of malignant tumors, precancerous lesions or benign lesions. The invention also relates to pharmaceutical compositions comprising such novel compounds, their use and preparation methods.

The present invention relates to the use of lipid/fat droplet deposits in retinas of a human subject as a biomarker for diagnosing, prognosing, and/or monitoring retinal neurodegeneration with or without an elevated intraocular pressure in glaucoma.

Methods and compositions are provided for hybrid telodendrimers and nanocarriers containing such hybrid telodendrimers.

Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing αvβ3 and αvβ5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin. TRNT may be administered alone or in combination with standard-of-care; an immunooncologic and/or chemotherapeutic, adjuvantly or neoadjuvantly.

Disclosed are chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R.sup.1, R.sup.1′, R.sup.2, R.sup.2′, R.sup.3, R.sup.3′, L.sup.1, L.sup.1′, L.sup.2 and L.sup.2′ are defined as in the claims, with metallic cations, especially Pb(II) and Bi(III). Also disclosed are bifunctional do2pa derivatives ligands of formula (I), as well as the use of chelates in nuclear medicine and the use of ligands in cations detection or epuration of effluents.

##STR00001##

Provided is a T1 contrast agent for magnetic resonance imaging. The T1 contrast agent includes fine iron oxide nanoparticle cores and micelles encapsulating the core particles. The micelles include a nonionic surfactant consisting of a hydrophilic moiety containing at least two chains and a hydrophobic moiety containing at least one C.sub.10-C.sub.30 hydrocarbon chain. The T1 contrast agent of the present invention is a novel one based on fine iron oxide nanoparticles that can replace conventional gadolinium-based T1 contrast agents. The T1 contrast agent based on fine iron oxide nanoparticles according to the present invention is harmless to humans, is rapidly distributed in the blood, and has a uniform size, ensuring its uniform contrast effect. In addition, the T1 contrast agent of the present invention enables image observation for at least 1 hour to up to 2 hours and is excreted through the kidneys and liver. Therefore, the T1 contrast agent of the present invention avoids the problems encountered in conventional gadolinium-based contrast agents.

Compositions, formulations, and kits comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to reporter molecules including fluorescent dyes or conjugated to cytotoxic agents. Dosing and pharmacokinetic profiles for therapeutic and diagnostic applications using chlorotoxin conjugate compounds are provided.

A method of preparing a .sup.64Cu-BaBaSar-RGD.sub.2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD.sub.2 and adding a .sup.64Cu solution to the lyophilized BaBaSar-RGD.sub.2.